QUARTERLY REPORT ON CONSOLIDATED RESULTS FOR THE THIRD FINANCIAL QUARTER ENDED 31 MARCH 2024 (The figures have not been audited)

CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

| | | Indiv | Individual Quarter | | ative Quarter |
|--|-------|----------|--------------------|------------|---------------|
| | | Current | Corresponding | 9 Months | 9 Months |
| | | Quarter | Quarter | Cumulative | Cumulative |
| | | Ended | Ended | To Date | To Date |
| | | 31-03-24 | 31-03-23 | 31-03-24 | 31-03-23 |
| | Note | RM'000 | RM'000 | RM'000 | RM'000 |
| Revenue | | 55,878 | 59,396 | 166,733 | 186,399 |
| Operating expenses | | (44,818) | (42,543) | (131,937) | (136,020) |
| Other operating income | | 2,854 | 897 | 4,925 | 2,383 |
| Profit from operations | • | 13,914 | 17,750 | 39,721 | 52,762 |
| Finance cost | | (5) | (67) | (34) | (174) |
| Profit before tax | • | 13,909 | 17,683 | 39,687 | 52,588 |
| Tax expense | (B6) | (7,075) | (188) | (7,577) | (442) |
| Profit after tax, representing total comprehensive income for the period | • | 6,834 | 17,495 | 32,110 | 52,146 |
| Earnings per share (sen) | : | 0,034 | 17,450 | 32,110 | 52,140 |
| Zarim.85 per simie (seri) | | | | | |
| (a) Basic | (B12) | 4.61 | 11.82 | 21.65 | 35.23 |
| (b) Diluted | (B12) | 4.61 | 11.82 | 21.65 | 35.23 |

(The Condensed Consolidated Statement of Profit Or Loss And Other Comprehensive Income should be read in conjunction with the Audited Financial Statements for the year ended 30 June 2023 and the accompanying explanatory notes attached to this interim financial report)

QUARTERLY REPORT ON CONSOLIDATED RESULTS FOR THE THIRD FINANCIAL QUARTER ENDED 31 MARCH 2024 (The figures have not been audited)

CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

| | | Unaudited As at 31-03-24 | Audited As at 30-06-23 |
|---|--------|---------------------------------------|---------------------------|
| | Note | RM '000 | RM '000 |
| ASSETS | | | |
| Non-Current Assets | | | |
| Property, plant and equipment | | 152,351 | 126,366 |
| Investment properties | | 1,293 | 1,312 |
| Right-of-use assets | | 9,812 | 10,634 |
| Deferred tax assets | | 1,698 | 6,791 |
| Current Assets | | 165,154 | 145,103 |
| | | F4 000 | F0.200 |
| Inventories | | 54,098 33,271 | 59,200 |
| Trade receivables | | , , , , , , , , , , , , , , , , , , , | 34,556 |
| Other receivables, deposits and prepayments | | 2,717 | 2,471 |
| Tax recoverable Short term investment | | 25 | 045 |
| | | - EE 401 | 945 |
| Fixed deposits with licensed bank Cash and bank balances | | 55,401 | 80,654 |
| Cash and bank balances | | 4,806 150,318 | 7,353 185,179 |
| TOTAL ASSETS | | 315,472 | 330,282 |
| | | | · |
| EQUITY AND LIABILITIES | | | |
| Equity attributable to equity holders of the par- | ent | | |
| Share capital | | 86,276 | 84,896 |
| Share option reserve | | - | 153 |
| Retained earnings | | 176,677 | 186,030 |
| N 6 (7) 1999 | | 262,953 | 271,079 |
| Non-Current Liabilities | | | |
| Lease liabilities | | 82 | 82 |
| Deferred Income | | 613 | 823 |
| Current Liabilities | | 695 | 905 |
| Trade payables | | 16,230 | 20,554 |
| Other payables and accruals | | 33,179 | 36,564 |
| Lease liabilities | | 244 | 964 |
| Current tax liabilities | | 2,171 | 216 |
| Short term borrowings | (B8) | 2,171 | 210 |
| Short term borrowings | (DO) | 51,824 | 58,298 |
| Total Liabilities | | 52,519 | 59,203 |
| TOTAL EQUITY AND LIABILITIES | | 315,472 | 330,282 |
| | | | 000,202 |
| Net assets per share attributable to ordinary | | | |
| equity holders of the parent (RM) | (B13) | 1.77 | 1.83 |

(The Condensed Consolidated Statement of Financial Position should be read in conjunction with the Audited Financial Statements for the year ended 30 June 2023 and the accompanying explanatory notes attached to this interim financial report)

QUARTERLY REPORT ON CONSOLIDATED RESULTS FOR THE THIRD FINANCIAL QUARTER ENDED 31 MARCH 2024 (The figures have not been audited)

CONDENSED CONSOLIDATED STATEMENT OF CASH FLOW

| | 9 Months Ended 31-03-24 RM '000 | 9 Months Ended 31-03-23 RM '000 |
|--|--|--|
| Cash Flows From Operating Activities | | |
| Profit before taxation | 39,687 | 52,588 |
| Adjustment for: Property, plant and equipment written off Impairment loss on trade receivables | 40 | 36 336 |
| Depreciation of property, plant and equipment and investment properties | 9,972 | 10,142 |
| Depreciation of right-of-use assets Fair value gain on derivatives financial instrument | 822 | 859 (15) |
| Unrealised (gain)/loss on foreign exchange | (35) | 637 |
| Provision for inventories obsolescence | 166 | 1,692 |
| Amortisation of deferred income | | |
| | (210) 34 | (221) 174 |
| Interest expense Interest income | (3,043) | (1,867) |
| Share based payment under ESOS | 44 | (1,007) |
| Operating profit before working capital changes | 47,477 | 64,361 |
| Decrease/(Increase) in inventories | 4,936 | (12,206) |
| Decrease in receivables | 1,762 | 2,735 |
| (Decrease)/Increase in payables | (7,709) | 1,789 |
| Cash generated from operations | 46,466 | 56,679 |
| Tax paid | (554) | (114) |
| Net cash from operating activities | 45,912 | 56,565 |
| Cash Flows For Investing Activities | | |
| Interest received | 3,043 | 1,867 |
| Withdrawal / (Placement) of fixed deposit with tenure more than 3 months | 9,667 | (9,667) |
| Purchase of property, plant and equipment | (35,978) | (26,680) |
| Net cash for investing activities | (23,268) | (34,480) |

KOTRA INDUSTRIES BERHAD (497632-P)

QUARTERLY REPORT ON CONSOLIDATED RESULTS FOR THE THIRD FINANCIAL QUARTER ENDED 31 MARCH 2024 (The figures have not been audited)

CONDENSED CONSOLIDATED STATEMENT OF CASH FLOW (continued)

| | 9 Months Ended 31-03-24 RM '000 | 9 Months Ended 31-03-23 RM '000 |
|---|---|---|
| Cash Flows For Financing Activities | | |
| Dividend paid Repayment of lease liabilities Repayment of term loans Proceeds from issuance of shares Interest paid Net cash for financing activities | (41,528) (720) - 1,248 (34) (41,034) | (38,479) (721) (5,549) 57 (174) (44,866) |
| Net Decrease in Cash & Cash Equivalents | (18,390) | (22,781) |
| Effect of Exchange Rate Changes on Cash & Cash Equivalents | (688) | (540) |
| Cash & Cash Equivalents at beginning of the financial period | 79,285 | 89,716 |
| Cash & Cash Equivalents at end of financial period | 60,207 | 66,395 |
| The Cash & Cash Equivalents Comprise The Following:- | | |
| Fixed deposits with licensed bank | 55,401 | 69,628 |
| Short term investment | - | 945 |
| Cash and bank balances | 4,806 | 5,489 |
| | 60,207 | 76,062 |
| Less: Fixed deposit with tenure more than 3 months | | (9,667) |
| | 60,207 | 66,395 |

(The Condensed Consolidated Statement of Cash Flow should be read in conjunction with the Audited Financial Statements for the year ended 30 June 2023 and the accompanying explanatory notes attached to this interim financial report)

QUARTERLY REPORT ON CONSOLIDATED RESULTS FOR THE THIRD FINANCIAL QUARTER ENDED 31 MARCH 2024 (The figures have not been audited)

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

| | Share Capital RM '000 | Non - distributable Share Option Reserve RM '000 | Distributable Retained Profits RM '000 | Total RM '000 |
|--|-----------------------------|--|---|------------------|
| As at 31 March 2024 | | | | |
| Balance at 1 July 2023 | 84,896 | 153 | 186,030 | 271,079 |
| Profit after tax, representing total comprehensive income for the year | - | - | 32,110 | 32,110 |
| Dividend paid | - | - | (41,528) | (41,528) |
| Share options exercised | 1,380 | (132) | - | 1,248 |
| Share based payment transactions | - | 44 | - | 44 |
| Share options expired transferred to retained earnings* | - | (65) | 65 | - |
| Balance at 31 March 2024 | 86,276 | - | 176,677 | 262,953 |
| As at 31 March 2023 | | | | |
| As at 1 July 2022 | 84,766 | 99 | 159,275 | 244,140 |
| Profit after tax, representing total comprehensive income for the year | - | - | 52,146 | 52,146 |
| Dividend paid | - | - | (38,479) | (38,479) |
| Share options exercised | 75 | (18) | - | 57 |
| Balance at 31 March 2023 | 84,841 | 81 | 172,942 | 257,864 |

^{*}Balance in share options reserve is transferred to the retained earnings upon expiry of ESOS period on 29 July 2023.

(The Condensed Consolidated Statement of Changes in Equity should be read in conjunction with the Audited Financial Statements for the year ended 30 June 2023 and the accompanying explanatory notes attached to this interim financial report)

QUARTERLY REPORT ON CONSOLIDATED RESULTS FOR THE THIRD FINANCIAL QUARTER ENDED 31 MARCH 2024

A. Explanatory Notes pursuant to MFRS 134 Interim Financial Reporting

A1. Accounting Policies and Methods of Computation

The interim financial statements have been prepared in accordance with MFRS 134, Interim Financial Reporting and paragraph 9.22 of the Bursa Malaysia Securities Berhad Main Market Listing Requirements. The figures for the cumulative period in the current quarter to 31 March 2024 have not been audited. The interim financial statements should be read in conjunction with the audited financial statements of the Group for the financial year ended 30 June 2023.

The significant accounting policies adopted by the Group in this interim financial report are consistent with those adopted in the annual audited financial statements for the financial year ended 30 June 2023 except for those mentioned in paragraph A1.1 below.

A1.1 During the current financial period, the Group has adopted the following new Malaysian Financial Reporting Standards and interpretations (including the consequential amendments , if any) which were effective for the financial periods beginning on or after 1 January 2023:-

MFRSs and IC Interpretations (Including The Consequential Amendments)

Amendments to MFRS 101: Disclosure of Accounting Policies;

Amendments to MFRS 108: Definition of Accounting Estimates;

Amendments to MFRS 112: Deferred Tax related to Assets and Liabilities arising from

a Single Transaction; and

Amendments to MFRS 112: International Tax Reform - Pillar Two Model Rules.

The adoption of the above Malaysian Financial Reporting Standards and/or IC interpretations (including the consequential amendments, if any) did not have any material impact on the Group's financial statements for the period under review.

A1.2 The Group has not applied in advance the following Malaysian Financial Reporting Standards and interpretations (including the consequential amendments, if any) that have been issued by the Malaysian Accounting Standards Board (MASB) but are not yet effective for the current financial period:

| MFRSs and IC Interpretations (Including The Consequential Amendments) | Date |
|---|-----------|
| Amendments to MFRS 16: Lease Liability in a Sale and Leaseback | 01-Jan-24 |
| Amendments to MFRS 101: Classification of Liabilities as Current or Non-current | 01-Jan-24 |
| Amendments to MFRS 101: Non-current Liabilities with Covenants | 01-Jan-24 |
| Amendments to MFRS 107 and MFRS 7: Supplier Finance Arrangements | 01-Jan-24 |
| Amendments to MFRS 121: Lack of Exchangeability | 01-Jan-25 |
| | |

The adoption of the above-mentioned Malaysian Financial Reporting Standards and IC interpretations (including the consequential amendments, if any), insofar as they are applicable to the Group, is expected to have no material impact on the financial statements of the Group upon their initial application.

A2. Seasonal or Cyclical Factors

The business operation of the Group was not materially affected by any seasonal or cyclical factors.

A3. Unusual items affecting Assets, Liabilities, Equity, Net Income or Cash Flows

There were no items affecting the assets, liabilities, equity, net income or cash flows that were unusual because of their nature, size or incidence.

Effective

QUARTERLY REPORT ON CONSOLIDATED RESULTS FOR THE THIRD FINANCIAL QUARTER ENDED 31 MARCH 2024

A4. Changes in Estimates

There were no changes in estimates reported in prior interim periods of the current financial year or prior financial years which have a material effect in the current interim period.

A5. Issues, Repurchases and Repayments of Debt and Equity Securities

There were no issues, repurchases or repayments of debt and equity securities, for the period ended 31 March 2024 except for the issuance of 250,000 ordinary shares that was issued in July 2023 pursuant to the Company's Employee Share Option Scheme at the exercise price of RM4.99 each.

A6. Dividend Paid

A second interim single tier dividend of 15.5 sen per ordinary share in respect of the financial year ended 30 June 2023 amounting to RM22,988,682 was paid on 12 October 2023.

An interim single tier dividend of 12.5 sen per ordinary share in respect of the financial year ending 30 June 2024 amounting to RM18,539,261 was paid on 21 March 2024.

A7. Segmental Information

In determining the geographical segments of the Group, sales are based on the country in which the customer is located.

Non-current assets are determined according to the country where these assets are located. The amounts of non-current assets do not include financial instruments and deferred tax assets.

The segment information in respect of the Group's operating segments for the period ended 31 March 2024 is as follows:

| | Reve | nue | Reve | nue | Non-curre | nt assets |
|----------|---------|---------|---------|---------|-----------|-----------|
| | Current | Quarter | 9 Moi | nths | 9 Mo | nths |
| | Ended 3 | 31 Mar | Ended 3 | 1 Mar | Ended 3 | 31 Mar |
| | 2024 | 2023 | 2024 | 2023 | 2024 | 2023 |
| | RM'000 | RM'000 | RM'000 | RM'000 | RM'000 | RM'000 |
| Malaysia | 38,060 | 41,012 | 112,425 | 126,718 | 163,456 | 128,050 |
| Overseas | 17,818 | 18,384 | 54,308 | 59,681 | - | - |
| | 55,878 | 59,396 | 166,733 | 186,399 | 163,456 | 128,050 |
| | | | - | | | |

Revenue is recognised at a point in time.

No other segmental information such as segment assets, liabilities and results is presented as the Group is principally engaged in pharmaceutical and healthcare products manufacturing and trading business and operates from Malaysia only.

Revenue from one major customer (quarter ended 31 March 2023 : one major customer), with revenue equal to or more than 10% of Group revenue, amounted to RM18.5 million (9 months ended 31 March 2023: RM22.0 million) arising from export sales.

A8. Events After the Interim Period

There were no material events after the quarter ended 31 March 2024 and up to 20 May 2024 that have not been reflected in these financial statements.

A9. Effect of Changes in the Composition of the Group

There were no changes in the composition of the Group, including business combinations, acquisition or disposal of subsidiaries and long term investments, restructuring, or discontinuance of operations during the period under review.

QUARTERLY REPORT ON CONSOLIDATED RESULTS FOR THE THIRD FINANCIAL QUARTER ENDED 31 MARCH 2024

A10. Changes in Contingent Liabilities or Contingent Assets

There were no contingent liabilities or contingent assets at the end of this reporting period and end of last financial year.

A11. Capital Commitments

The amounts committed for the purchase of property, plant and equipment not provided for in the interim financial statements are as follows:

| | As at | As at |
|---------------------------------|----------|----------|
| | 31-03-24 | 31-03-23 |
| | RM'000 | RM'000 |
| Contracted but not provided for | 93,537 | 37,618 |

A12. Significant Related Party Transactions

The Group's significant related party transactions for the current financial period ended 31 March 2024 are as follows:

| | Current Quarter Ended 31 Mar | | 9 Months Ended 31 Mar | |
|---|---------------------------------|----------------|--------------------------|----------------|
| | | | | |
| | 2024 RM'000 | 2023 RM'000 | 2024 RM'000 | 2023 RM'000 |
| Companies in which certain key management personnel | | | | |
| have significant financial interests: | | | | |
| - Lease payment on short term leases | 2 | 12 | 9 | 39 |
| - Lease payment for right-of-use asset | 246 | 246 | 738 | 738 |
| A company in which a close member of the family | | | | |
| of certain key management personnel has | | | | |
| significant financial interests: | | | | |
| - Sales of goods | (89) | (148) | (248) | (408) |

The above recurrent transactions were entered into based on normal commercial terms.

QUARTERLY REPORT ON CONSOLIDATED RESULTS FOR THE THIRD FINANCIAL QUARTER ENDED 31 MARCH 2024

B. Explanatory Notes pursuant to Appendix 9B of the Listing Requirements of Bursa Malaysia Securities Berhad

B1. Review of the Performance of the Group

(a) Performance of the current quarter against the preceding year corresponding quarter

| | Current (| Current Quarter | | |
|---|---|--|------------------------------|--|
| | Ended 3 | Ended 31 Mar | | |
| | 2024 | 2023 | % | |
| | RM'000 | RM'000 | | |
| Turnover | 55,878 | 59,396 | -5.92% | |
| Profit from operations | 13,914 | 17,750 | -21.61% | |
| Profit before tax | 13,909 | 17,683 | -21.34% | |
| Profit after tax (PAT) | 6,834 | 17,495 | -60.94% | |
| Net PAT margin | 12.23% | 29.45% | | |
| Profit from operations Profit before tax Profit after tax (PAT) | RM'000 55,878 13,914 13,909 6,834 | RM'000 59,396 17,750 17,683 17,495 | -5.92% -21.61% -21.34% | |

The Group recorded a decrease in turnover of 5.92% for the current quarter ended 31 March 2024 as compared to the corresponding quarter ended 31 March 2023. This was mainly due to a decrease in the sales of pharmaceutical products in local and export markets as well as supplement products in local market.

The Group recorded a profit before tax of RM13.91 million for current quarter ended 31 March 2024 as compared to a profit before tax of RM17.68 million in corresponding quarter of the preceding year. The decline in profit before tax was mainly due to product mix and lower sales, compounded by certain expenses which were relatively fixed in nature.

The decrease in the profit after tax margin from 29.45% to 12.23% was mainly due to income tax expense related to the Group's 9 months business profit and interest income, as well as the reversal of deferred tax assets arising from the utilisation of tax losses and incentives brought forward. This resulted in a higher tax payable compared to the corresponding quarter.

(b) Performance of the current period against the preceding year corresponding period

| | 9 Mo: | | |
|------------------------|--------------|---------|---------|
| | Ended 31 Mar | | Changes |
| | 2024 | 2023 | % |
| | RM'000 | RM'000 | |
| Turnover | 166,733 | 186,399 | -10.55% |
| Profit from operations | 39,721 | 52,762 | -24.72% |
| Profit before tax | 39,687 | 52,588 | -24.53% |
| Profit after tax (PAT) | 32,110 | 52,146 | -38.42% |
| Net PAT margin | 19.26% | 27.98% | |

The Group recorded a decrease in turnover of 10.55% for the current period ended 31 March 2024 as compared to the corresponding 9 months ended 31 March 2023. In the corresponding quarter ended 31 March 2023, there was an increase in demand for medication from the local market, where there were major shortages of various prescriptions items in the country. This demand began to normalise subsequent to that quarter.

In the current period ended 31 March 2024, there was a decrease in sales of supplement products to the export and local market

The Group recorded a profit before tax of RM39.69 million for the 9 months ended 31 March 2024 as compared to a profit before tax of RM52.59 million for the 9 months ended 31 March 2023. The lower profit before tax was primarily due to lower sales while certain expenses were relatively fixed in nature.

Profit after tax margin decreased from 27.98% to 19.26% mainly due to income tax expense related to the Group's 9 months business profit and interest income, as well as the reversal of deferred tax assets arising from the utilisation of tax losses and incentives brought forward. This resulted in a higher tax payable compared to the corresponding quarter.

QUARTERLY REPORT ON CONSOLIDATED RESULTS FOR THE THIRD FINANCIAL QUARTER ENDED 31 MARCH 2024

B2. Comparison with Preceding Quarter's Results

| | Quarter Ended | | |
|------------------------|---------------|--------|---------|
| | 31 Mar | 31 Dec | Changes |
| | 2024 | 2023 | % |
| | RM'000 | RM'000 | |
| Turnover | 55,878 | 57,546 | -2.90% |
| Profit from operations | 13,914 | 11,890 | 17.02% |
| Profit before tax | 13,909 | 11,882 | 17.06% |
| Profit after tax (PAT) | 6,834 | 11,616 | -41.17% |
| Net PAT margin | 12.23% | 20.19% | |

For the quarter ended 31 March 2024, the Group recorded a decrease in revenue of 2.90% to RM55.88 million as compared to RM57.55 million in the preceding quarter. This was mainly due to decreased sales to the export market for pharmaceutical products partly offset by increase in sales in the local market for pharmaceutical products.

The Group recorded a profit before tax of RM13.91 million in the current quarter as compared to the profit before tax of RM11.88 million in the preceding quarter. The increase in net profit margin was mainly due to the foreign exchange gain recorded in the current quarter.

B3. Current Year Prospects

The prevailing economic uncertainty is a result of a complex global landscape, marked by inflationary pressures and exchange rate volatility. This situation, characterized by rising inflation and weak local currency, is likely to persist for the remaining financial year 2024, potentially driving up operational costs.

Furthermore, the challenging economic environment may weaken consumer purchasing power, ultimately leading to reduced demand for non-essential pharmaceutical products, which could, in turn, impact pharmaceutical sales.

Despite these formidable challenges, the Board is committed to prudent decision-making and will proactively monitor and review the Group's strategic plans in its quest to create sustainable value for shareholders.

Although the current market sentiment reflects an uncertain economic outlook, the Board remains positive in the Group's prospects. Given the sustained demand for its products, the Group anticipates continued profitability throughout the financial year ending 30 June 2024.

B4. Variance of Actual Profit from Forecast Profit or Profit Guarantee

The Group did not issue any profit forecast or profit guarantee in the current quarter or in the prior financial period.

B5. Statement by Directors

The Group did not disclose or announce any profit forecast or projection in a public document in the current quarter or prior financial period.

Onartor

B6. Breakdown of Tax Charges

| | Ended 31 Mar | | Ended 31 Mar | |
|---|--------------|----------|--------------|--------|
| | | | | |
| | 2024 | 2023 | 2024 | 2023 |
| | RM'000 | RM'000 | RM'000 | RM'000 |
| Income tax: | | | | |
| - Current tax expense | 1,982 | 188 | 2,484 | 442 |
| Deferred Taxation | | | | |
| - Origination and reversal of temporary differences | 5,093 | <u>-</u> | 5,093 | - |
| Total tax expenses | 7,075 | 188 | 7,577 | 442 |
| | | | | |

The current income tax expense for the period under review relates to the profit from the Group's business and interest income of the Group. The reversal of recognised deferred tax assets, due to the utilisation of the brought forward tax allowances and incentives. The Group recognises tax liabilities based on prevailing tax laws and approved financial reporting standard on deferred taxation.

0 Months

QUARTERLY REPORT ON CONSOLIDATED RESULTS FOR THE THIRD FINANCIAL QUARTER ENDED 31 MARCH 2024

B7. Status of Corporate Proposals

There were no corporate proposals announced by the Company as at the date of the issue of this quarterly report.

B8. Details of Group Borrowings and Debt Securities

The Group's borrowings as at the end of this financial period were as follows:

| | As at | As at |
|---------------------------|----------|----------|
| | 31-03-24 | 31-03-23 |
| | RM'000 | RM'000 |
| (a) Short Term Borrowings | | |
| Secured | | |
| Term loan | - | 1,122 |
| | - | 1,122 |
| (b) Long Term Borrowings | | |
| Secured | | |
| Term loan | - | - |
| | - | |

B9. Material Litigation

There was no material litigation since the financial period ended 31 March 2024 and up to 20 May 2024.

B10. Dividend Declared

No dividend has been proposed in respect of the current financial period ended 31 March 2024.

B11. Profit before tax

| | Quarter Ended 31 Mar | | 9 Months Ended 31 Mar | |
|---|-------------------------|--------|--------------------------|---------|
| | | | | |
| | 2024 | 2023 | 2024 | 2023 |
| | RM'000 | RM'000 | RM'000 | RM'000 |
| Profit before tax is arrived at after (crediting)/charging: | | | | |
| Interest income | (930) | (798) | (3,043) | (1,867) |
| Other income | (114) | (25) | (285) | (279) |
| Depreciation of property, plant and equipment and | 3,281 | 3,357 | 9,972 | 10,142 |
| investment properties | | | | |
| Depreciation of right-of-use assets | 274 | 286 | 822 | 859 |
| Amortisation of deferred income | (66) | (74) | (210) | (221) |
| Impairment loss on trade receivables | - | 336 | - | 336 |
| Property, plant and equipment written off | - | 36 | 40 | 36 |
| Provision for/(Write-back of) inventories obsolescence | 663 | (267) | 166 | 1,692 |
| Foreign exchange (gain)/loss | | | | |
| - realised | (864) | 399 | (1,352) | (396) |
| - unrealised | (881) | (599) | (35) | 637 |
| Fair value gain on derivatives financial instrument | _ | - | - | (15) |

There was no gain or loss on disposal of quoted or unquoted investment or properties nor any exceptional items for the current quarter and financial period ended 31 March 2024.

QUARTERLY REPORT ON CONSOLIDATED RESULTS FOR THE THIRD FINANCIAL QUARTER ENDED 31 MARCH 2024

B12. Earnings Per Share

| | | Quarter Ended 31 Mar 2024 2023 | | 9 Months Ended 31 Mar 2024 2023 | |
|------|---|--------------------------------------|---------------|---------------------------------------|---------------|
| | (a) Basic Earnings Per Share | | | | |
| | Net Profit attributable to shareholders (RM'000) | 6,834 | 17,495 | 32,110 | 52,146 |
| | Weighted average number of ordinary shares ('000) | 148,296 | 147,998 | 148,296 | 147,998 |
| | Basic Earnings per share (sen) | 4.61 | 11.82 | 21.65 | 35.23 |
| | (b) Diluted Earnings Per Share | | | | |
| | Net Profit attributable to shareholders (RM'000) | 6,834 | 17,495 | 32,110 | 52,146 |
| | Weighted average number of ordinary shares ('000) Adjustment for ESOS ('000) | 148,296 | 147,998 31 | 148,296 | 147,998 31 |
| | ., | 148,296 | 148,029 | 148,296 | 148,029 |
| | Diluted Earnings per share (sen) | 4.61 | 11.82 | 21.65 | 35.23 |
| B13. | Net assets per share | Unaudited As at 31-03-24 | | Audited As at 30-06-23 | |
| | Number of ordinary shares issued ('000) | 148,314 | : | 148,064 | |
| | Net assets per share attributable to ordinary equity holders of the parent (RM) | 1.77 | : | 1.83 | |

B14. Audit Report

The auditors' report on the Group's annual financial statements for the year ended 30 June 2023 did not contain any qualification.

BY ORDER OF THE BOARD

CHUA SIEW CHUAN Secretary

Date: 20 May 2024